IRUBIS GmbH
Entry last updated on May 17, 2016

The TUM spin-off IRUBIS offers continuous monitoring of bioreactors for the production of biopharmaceuticals.

Biopharmaceuticals are drugs which are produced by mammalian cells in so-called bioreactors. A major challenge is to ensure the optimal nutrient concentration (e.g. glucose) for these cells during the production process. This is why samples need to be taken and analyzed manually every day to adjust the supply.

To simplify and automize this costly process, IRUBIS developed Monipa. This device allows continuous monitoring and control of glucose, lactate and other parameters inside the bioreactor. Monipa is based on a well-established analytical method, mid-infrared spectroscopy, and includes a novel spectroscopy sensor and machine-learning software. Exchangeable single-use flow cells allow the monitoring of several bioreactors at the same time.

Facts
 
Contact
 

2016

Founding year

Stage

Company location

IRUBIS GmbH
Bayerstraße 85a
80335 Munich

[AdditionalInfo]
[Fundings] [Analytics] [Insights]

You might also be interested in

Irubis

Deals

Irubis secures pre-Series A financing

With the current financing, the Munich-based biotech company intends to further expand its Monipa measurement system.

Irubis

Deals

2.8 million euros seed financing for Irubis

The biotech startup Irubis has completed a €2.8 million seed financing round. High-Tech Gründerfonds (HTGF), Verve Ventures, and Ventura BioMed, as well as…

Irubis

Deals

Irubis receives 1.3 million euros from EU project

The Munich-based biotech startup Irubis has received €1.3 million in funding under the EU's Horizon 2020 funding program. The individual project of the European Innovation Council (EIC) has…